Actively Recruiting
Do we Miss a Common Subset of Primary Aldosteronism in Which There is Cyclical or Exaggerated Diurnal Variation in Secretion?
Led by Queen Mary University of London · Updated on 2025-06-08
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating whether measuring aldosterone levels in a 24-hour urine sample can better detect Primary Aldosteronism (PA), a condition causing high blood pressure. The study also explores if aldosterone production varies during the day or follows a cyclical pattern in people with this condition. Understanding these patterns may help diagnose more individuals with PA, especially those with variable aldosterone levels. Participants will provide a 24-hour urine sample to measure aldosterone metabolites. They will also undergo multiple blood tests throughout the day to assess changes in aldosterone secretion. This observational study does not involve treatment but focuses on evaluating aldosterone patterns over a 12-month period. During the study, participants will be monitored with urine and blood tests to measure aldosterone levels and variability. Researchers will analyze the sensitivity and specificity of the 24-hour urine test, compare day and night urine measurements, and observe variations in aldosterone secretion. Outcomes include clinical and biochemical cure rates in those who may undergo adrenalectomy. The study lasts at least 12 months, with ongoing assessments during this time.
CONDITIONS
Brief Title
Diagnosing Variable Primary Aldosteronism.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- People with suspected Primary Aldosteronism based on low renin, high plasma sodium, or low plasma potassium
- Patients diagnosed with Primary Aldosteronism but with aldosterone levels below 277 pmol/L
- Patients with aldosterone test results showing variability at different times
- Willingness to consent and participate in the study
You will not qualify if you...
- Inability to stop beta-adrenoceptor blocker therapy for two weeks
- Receiving end-of-life treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 months
Participants provide 24-hour urine samples and multiple blood tests throughout the day to assess aldosterone secretion variability.
Multiple visits during the day for blood tests and 24-hour urine collection
Trial Site Locations
Total: 1 location
1
Queen Mary University of London
London, United Kingdom
Actively Recruiting
Research Team
Y
Yun Ni Lee
T
Tumi Kaminskas
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here